Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab in Advanced Non-Clear Cell Renal Cell Carcinoma

Next Previous
Search
Trial Profile

A Phase 2 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab in Advanced Non-Clear Cell Renal Cell Carcinoma

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 06 Mar 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Most Recent Events

  • 03 Mar 2025 Status changed from recruiting to active, no longer recruiting.
  • 06 Jun 2023 Results (At data cut-off: 9 Dec 2022; n=40) presented at the 59th Annual Meeting of the American Society of Clinical Oncology.
  • 01 Aug 2022 Planned End Date changed from 20 Dec 2024 to 20 Dec 2025.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top